Stock comparison
Alnylam Pharmaceuticals
United Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ALNY
Alnylam Pharmaceuticals
Market cap
$39.71B
Sector
Healthcare
UTHR
United Therapeutics
Market cap
$24.13B
Sector
Healthcare
Overall winner
Alnylam Pharmaceuticals ALNY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ALNY | UTHR | Winner |
|---|---|---|---|
| Warren Buffett | 58C | 71B | UTHR |
| Benjamin Graham | 80D | 76B | ALNY |
| Philip Fisher | 79B | 76B | ALNY |
| Peter Lynch | 81A | 62C | ALNY |
| Joel Greenblatt | 63C | 46D | ALNY |
| Charlie Munger | 75D | 64C | ALNY |
| Terry Smith | 75B | 64C | ALNY |
Side-by-side metrics
| Metric | ALNY | UTHR |
|---|---|---|
| Market cap | $39.71B | $24.13B |
| P/E (TTM) | 66.1x | 19.2x |
| EV/EBIT | 75.5x | 15.2x |
| ROIC (TTM) | 19.66% | 18.81% |
| Gross margin | 80.89% | 86.58% |
| Net margin | 13.46% | 40.61% |
| Revenue CAGR 5y | 44.82% | 17.22% |
| EPS CAGR 5y | 38.42% | 29.84% |
| Debt / Equity | 1.2x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ALNY leads on
- Revenue CAGR 5y44.82%vs 17.22%+62%
- Market cap$39.71Bvs $24.13B+39%
- EPS CAGR 5y38.42%vs 29.84%+22%
UTHR leads on
- Debt / Equity-vs 1.2x+100%
- EV/EBIT15.2xvs 75.5x+80%
- P/E (TTM)19.2xvs 66.1x+71%
- Net margin40.61%vs 13.46%+67%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.